Skip to main content
Triangle logo TriangleGet started

Imlunestrant (NCT07287098)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer: a one-minute explainerNCT072870981 min

Imlunestrant trial for Breast Neoplasms (NCT07287098). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for premenopausal women 18 or older with ER-positive, HER2-negative early breast cancer. One group has untreated stage I–III disease with Ki-67 at least 10%; another has resected disease after qualifying endocrine therapy.

The idea: oral imlunestrant degrades estrogen receptors to block growth signaling. The short-treatment group compares imlunestrant alone, imlunestrant with ovarian-suppressing goserelin injections, and tamoxifen, measuring proliferation through day 29. The second group compares imlunestrant against tamoxifen without ovarian suppression, assessing ovarian cysts over six months.

This phase 2 study plans 600 patients. Lilly sponsors six recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.